It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Explore the best long term stocks to buy for sustained growth. Make wise investments that can pay off in the future.
27,330 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
As IPOs continue to attract capital, one recent entrant stands out. This article breaks down why wall street expects ...
Tech chipmakers pull back Friday after a brisk rally, with Intel leading declines and Nvidia slipping ahead of earnings.
Investors looking at cannabis real estate need to understand how Innovative Industrial Properties reports earnings. T...
A wave of altcoins posted double-digit gains while Bitcoin steadied. Learn which coins led the rally, why it happened...
Young couples are grappling with recurring requests from in-laws who take vacations, risking long-term savings. Exper...
As ATS gears up for its Q4 2026 results, investors want clarity on revenue momentum, margins, and guidance. This arti...
A reality-TV star running for Los Angeles mayor isn’t just drama—it’s a real test of how city budgets, taxes, and pub...
When a public tribute shines a light on mentors and fathers, it offers more than sentiment—it's a blueprint for famil...
Meta Platforms is nudging into cloud computing, aiming to monetize idle compute and AI-ready infrastructure. This art...
The sudden death of a young boxer underscores a harsher truth: income can vanish fast, and financial security for ath...
Walmart and Target are more than discount stores. Their revenue trends reveal how they adapt to inflation, supply cha...